At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 215 enrolled
Drug / intervention
albiglutide +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Dose Finding Study of GSK716155 Versus Placebo in the Treatment of Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating albiglutide and placebo for Diabetes Mellitus, Type 2. Completed, enrolled 215 participants across 30 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, multicenter, 4-parallel-group, dose ranging study evaluating the dose response, efficacy and safety of subcutaneously injected GSK716155 (albiglutide) in Japanese subjects with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedApr 2010
Primary CompletionMay 2011
TodayJul 2026
First PostedApr 2, 2010
Enrollment StartApr 1, 2010
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.3 years ago
Interventions
albiglutidebiological
subcutaneous injection of albiglutide
placebobiological
subcutaneous injection of placebo to match albiglutide